Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Maravai Lifesciences Holdings (MRVI) EBIAT (2020 - 2025)

Maravai Lifesciences Holdings has reported EBIAT over the past 6 years, most recently at -$63.0 million for Q4 2025.

  • Quarterly results put EBIAT at -$63.0 million for Q4 2025, down 36.79% from a year ago — trailing twelve months through Dec 2025 was -$158.1 million (up 8.94% YoY), and the annual figure for FY2025 was -$230.8 million, up 11.12%.
  • EBIAT for Q4 2025 was -$63.0 million at Maravai Lifesciences Holdings, down from -$25.6 million in the prior quarter.
  • Over the last five years, EBIAT for MRVI hit a ceiling of $308.1 million in Q4 2022 and a floor of -$106.0 million in Q4 2023.
  • Median EBIAT over the past 5 years was -$12.0 million (2023), compared with a mean of $28.9 million.
  • Biggest five-year swings in EBIAT: soared 9227.12% in 2021 and later tumbled 17926.87% in 2024.
  • Maravai Lifesciences Holdings' EBIAT stood at $127.1 million in 2021, then soared by 142.38% to $308.1 million in 2022, then plummeted by 134.39% to -$106.0 million in 2023, then surged by 56.52% to -$46.1 million in 2024, then crashed by 36.79% to -$63.0 million in 2025.
  • The last three reported values for EBIAT were -$63.0 million (Q4 2025), -$25.6 million (Q3 2025), and -$39.6 million (Q2 2025) per Business Quant data.